1160683-38-4

Basic information

• Product Name: methyl 2-amino-4-bromo-6-fluoro-3-nitro-benzoate
• Synonyms: methyl 2-amino-4-bromo-6-fluoro-3-nitro-benzoate
• CAS NO: 1160683-38-4
• Molecular Weight: 293.049
• Mol File: 1160683-38-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: methyl 2-amino-4-bromo-6-fluoro-3-nitro-benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-amino-4-bromo-6-fluoro-3-nitro-benzoate(1160683-38-4)
• EPA Substance Registry System: methyl 2-amino-4-bromo-6-fluoro-3-nitro-benzoate(1160683-38-4)

Safety Data

• Hazardous Substances Data: 1160683-38-4(Hazardous Substances Data)

Upstream product

• 183065-68-1 4-bromo-2,6-difluorobenzoic acid 
• 773134-11-5 4-bromo-2,6-difluorobenzoic acid methyl ester 
• 1160683-37-3 methyl 4-bromo-2,6-difluoro-3-nitro-benzoate 

Downstream Products

• 1160683-39-5 methyl 2-amino-4-bromo-6-methoxy-3-nitro-benzoate 
• 1160683-41-9 6-hydroxy-8-phenyl-5-quinoxalinecarboxylic acid 
• 1160683-36-2 N-[(6-hydroxy-8-phenyl-5-quinoxalinyl)carbonyl]glycine 
• 1160683-43-1 ethyl N-[(6-hydroxy-8-phenyl-5-quinoxalinyl)carbonyl]glycinate 
• 1160684-96-7 N-{[6-hydroxy-8-(2-nitrophenyl)-5-quinoxalinyl]carbonyl}glycine 
• 1160684-43-4 N-{[8-(1-cyclohexen-1-yl)-6-hydroxy-5-quinoxalinyl]carbonyl}glycine 
• 1160684-95-6 N-{[6-hydroxy-8-(3-nitrophenyl)-5-quinoxalinyl]carbonyl}glycine 
• 1160684-46-7 N-{[8-(4-bromo-2-fluorophenyl)-6-hydroxy-5-quinoxalinyl]carbonyl}glycine 
• 1160684-76-3 N-{[8-(3,4-difluorophenyl)-6-hydroxy-5-quinoxalinyl]carbonyl}glycine 
• 1160684-45-6 N-{[8-(3-bromo-5-fluorophenyl)-6-hydroxy-5-quinoxalinyl]carbonyl}glycine 
• 1160684-44-5 N-({8-[2-fluoro-4-(trifluoromethyl)phenyl]-6-hydroxy-5-quinoxalinyl}carbonyl)glycine 

Relevant articles and documents

6-5 FUSED RINGS AS C5a INHIBITORS

The present disclosure provides, inter alia, Compounds of Formula (I) (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.

Condensed derivatives of imidazole useful as pharmaceuticals

The invention relates to the compounds (I) and their acids and bases salts: wherein: the dotted line indicates a double bond; X is N or C-R1 and Y is N or C-R2, X and Y not being simultaneously N; A is selected from the group consisting of phenyl, naphthyl and (5-11) membered monocyclic or bicyclic unsaturated cycle or heterocycle possibly substituted as defined in the application, and A can also comprise either a further (4-7) membered heterocycle, said heterocycle being a monocycle, fused, saturated or unsaturated, the polycyclic system then comprising up to 14 members and up to 5 heteroatoms selected from N, O and S; B is Hydrogen or a substituent as defined in the application, or B is a (4-10) membered mono or bicyclic saturated or unsaturated heterocycle containing 1-3 heteroatoms selected from N, O and S, and possibly substituted as defined in the application; B not being Hydrogen when X is N and Y is C-R2; R1 is Hydrogen or a substituent as defined in the application; B and R1 cannot be simultaneously Hydrogen; R2 is Hydrogen or Halogen; their preparation, their use in the antibacterial prevention and therapy, alone or in association with antibacterials, antivirulence agents or drugs reinforcing the host innate immunity, and pharmaceutical compositions and associations containing them.